ReviewJournal of inflammation research2025
From Gut to Lung: The Role of Bile Acids in Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut microbiota-immune-metabolic crosstalk in acute lung injury: integrating the gut-lung axis from mechanism to therapeutic targeting.Seminars in immunopathology · 2026Review
- Gut Microbial Functional Ecology and Microbiota-Derived Metabolites in Rheumatoid Arthritis Autoimmunity.Cells · 2026Review
- Explainable machine learning-based mortality prediction in critically ill patients with rheumatoid arthritis-associated lung disease: a radiomics and clinical data integration study.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a serious complication of rheumatoid arthritis (RA) that significantly increases both morbidity and mortality. Although advances have been made in elucidating the pathogenesis of RA-ILD, the specific roles of bile acids remain underexplored. Bile acids are known to modulate immune responses, potentially influencing the inflammatory processes central to RA-ILD; however, their exact mechanisms and therapeutic utility remain unclear. This review aims to elucidate the diverse functions of bile acids, highlighting their potential as both biomarkers of disease activity and as novel therapeutic agents to mitigate pulmonary inflammation and fibrosis. By exploring the gut-lung axis and the interactions between bile acid metabolism and immune responses, the review seeks to identify new avenues for RA-ILD treatment. It also discusses the emerging role of bile acid-derived exosomes in RA and RA-ILD, emphasizing their promise as vehicles for modulating inflammation. This review highlights the significance of current findings and the need for further studies to validate bile acids and their derivatives as reliable markers and effective therapies. By reviewing available research and identifying critical gaps for future research, this review aims to enhance our understanding of RA-ILD and to support the development of targeted interventions that could markedly improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.